OncoTherapy Science, Inc.
4564.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥8 | ¥9 | ¥8 | ¥7 |
| - Cash | ¥2 | ¥1 | ¥1 | ¥1 |
| + Debt | ¥0 | ¥0 | ¥0 | ¥0 |
| Enterprise Value | ¥7 | ¥7 | ¥7 | ¥6 |
| Revenue | ¥0 | ¥0 | ¥0 | ¥0 |
| % Growth | 14.4% | 7.9% | -44.7% | – |
| Gross Profit | ¥0 | -¥0 | ¥0 | ¥0 |
| % Margin | 14.1% | -1.8% | 5.9% | 12% |
| EBITDA | -¥0 | -¥0 | -¥0 | -¥0 |
| % Margin | -104.1% | -155.6% | -61.7% | -50.5% |
| Net Income | -¥0 | -¥0 | -¥0 | -¥0 |
| % Margin | -104.5% | -156% | -52.5% | -50.9% |
| EPS Diluted | -0.76 | -1.13 | -0.36 | -0.63 |
| % Growth | 32.7% | -213.9% | 42.9% | – |
| Operating Cash Flow | – | ¥0 | ¥0 | ¥0 |
| Capital Expenditures | – | ¥0 | ¥0 | ¥0 |
| Free Cash Flow | – | ¥0 | ¥0 | ¥0 |